\u6628\u5929\u94c1\u7c89\u7fa4\u91cc\u9762\u804a\u4e86\u94c1\u7c89\u533b\u751f\u63a8\u8350\u7684\u65b0\u51a0\u75c5\u6bd2\u6cbb\u7597\u836f\u7269\uff1a\u75c5\u6bd2\u7075\u3002<\/p>\n
\u7b2c\u4e00\u6b21\u542c\u8bf4\u8fd9\u4e2a\u836f\u7269\u80fd\u6cbb\u7597\u65b0\u51a0\u75c5\u6bd2\uff0c\u672c\u7740\u6c42\u771f\u52a1\u5b9e\u7684\u6001\u5ea6\u53bb\u7814\u7a76\u4e86\u4e00\u4e0b\uff0c\u5176\u5b9e\u662f\u6587\u732e\u68c0\u7d22+\u601d\u8003+\u7fa4\u53cb\u8ba8\u8bba\u3002<\/p>\n
\u672c\u6765\u60f3\u6628\u5929\u8bb0\u5f55\u4e00\u7b14\u7684\uff0c\u4f46\u662f\u65e0\u5948\u8ddf\u4e86\u621110\u5e74\u7684\u7535\u8111\u5d29\u4e86\u3002\u8a00\u5f52\u6b63\u4f20\uff0c\u75c5\u6bd2\u7075\u662f\u4ec0\u4e48\u836f\uff1f<\/p>\n
\u75c5\u6bd2\u7075\u6210\u5206\uff1a\u76d0\u9178\u5417\u5549\u80cd\uff08\u82f1\u6587\u540d\uff1amoroxydine hydrochloride\uff09\u3002<\/p>\n
\u75c5\u6bd2\u7075\u4f5c\u7528\uff1a\u80fd\u6291\u5236\u75c5\u6bd2\u7684DNA\u548cRNA\u805a\u5408\u9176\uff0c\u4ece\u800c\u6291\u5236\u75c5\u6bd2\u7e41\u6b96\u3002\u5728\u4eba\u80da\u80be\u7ec6\u80de\u4e0a\uff0c1%\u6d53\u5ea6\u5bf9DNA\u75c5\u6bd2(\u817a\u75c5\u6bd2\uff0c\u75b1\u75b9\u75c5\u6bd2)\u548cRNA\u75c5\u6bd2(\u57c3\u53ef\u75c5\u6bd2)\u90fd\u6709\u660e\u663e\u6291\u5236\u4f5c\u7528\uff0c\u5bf9\u75c5\u6bd2\u589e\u6b96\u5468\u671f\u5404\u4e2a\u9636\u6bb5\u5747\u6709\u6291\u5236\u4f5c\u7528\u3002\u5bf9\u6e38\u79bb\u75c5\u6bd2\u9897\u7c92\u65e0\u76f4\u63a5\u4f5c\u7528\u3002<\/p>\n
\u7531\u6b64\u770b\u6765\uff0c\u75c5\u6bd2\u7075\u662f\u5e7f\u8c31\u6297\u75c5\u6bd2\u836f\u7269\uff0c\u4f5c\u7528\u673a\u5236\u672a\u76f4\u63a5\u6291\u5236\u75c5\u6bd2\u590d\u5236\uff08\u7e41\u6b96\uff09\u3002\u65b0\u51a0\u75c5\u6bd2\u7684\u590d\u5236\u4e5f\u9700\u8981RNA\u805a\u5408\u9176\uff0c\u56e0\u6b64\u75c5\u6bd2\u7075\u6709\u53ef\u80fd\u5bf9\u65b0\u51a0\u75c5\u6bd2\u4e5f\u6709\u6291\u5236\u4f5c\u7528\u3002\u4f46\u5173\u952e\u662f\uff0c\u65b0\u51a0\u75c5\u6bd2\u7684\u6838\u7cd6\u6838\u9178\u805a\u5408\u9176RdRp\uff08\u4e5f\u662fRNA\u805a\u5408\u9176\uff09\u662f\u5426\u80fd\u88ab\u75c5\u6bd2\u7075\u6291\u5236\uff1f<\/p>\n
\u9996\u5148\u8f93\u5165\u75c5\u6bd2\u7075\u540e\uff0c\u6d4f\u89c8\u5668\u8df3\u51fa\u6765\u75c5\u6bd2\u7075\u88ab\u7981\u7528\u7684\u8bcd\u6761\u3002\u8fd9\u5413\u4e86\u4e00\u8df3\uff0c\u96be\u9053\u75c5\u6bd2\u7075\u6709\u4e25\u91cd\u836f\u7269\u4e0d\u826f\u53cd\u5e94\u88ab\u7981\u4e86\uff1f<\/p>\n
\u6df1\u5165\u4e86\u89e3\u4e86\u4e00\u4e0b\uff0c\u539f\u6765\u75c5\u6bd2\u7075\u88ab\u7981\u7528\u662f\u4e2a\u8bef\u4f20\uff0c\u88ab\u7981\u7684\u662f\u5730\u65b9\u836f\u54c1\u7ba1\u7406\u5c40\u6279\u51c6\u7684\u836f\u7269\uff0c\u56fd\u5bb6\u836f\u54c1\u7ba1\u7406\u5c40\u6279\u51c6\u7684\u836f\u7269\u4ecd\u7136\u662f\u6279\u51c6\u72b6\u6001\u3002<\/p>\n
\u68c0\u7d22\u53d1\u73b0moroxydine\u7528\u4e8e\u65b0\u51a0\u75c5\u6bd2\u6cbb\u7597\u56fd\u9645\u4e0a\u8fd8\u771f\u6709\u4eba\u505a\u4e86\u7814\u7a76\uff0c\u4f46\u662f\u53ea\u6709\u4e24\u7bc7\uff0c\u800c\u4e14\u5c5e\u4e8e\u634e\u5e26\u7684\u7814\u7a76\u3002\u7136\u800c\uff0c\u6709\u4e86\u8fd9\u4e24\u7bc7\u7814\u7a76\u62a5\u9053\uff0c\u6539\u5199\u4e86\u6211\u5bf9\u75c5\u6bd2\u7075\u6cbb\u7597\u65b0\u51a0\u75c5\u6bd2\u611f\u67d3\u7684\u770b\u6cd5\u3002<\/p>\n
\u5148\u8bf4\u7b2c\u4e00\u7bc7<\/p>\n
1. \u201cSARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System\u201d<\/p>\n
Biomedicines. 2021 Aug 11;9(8):996.<\/p>\n
doi: 10.3390\/biomedicines9080996.<\/p>\n
\u5148\u770b\u6458\u8981\uff1a<\/p>\n
\u51a0\u72b6\u75c5\u6bd22\u578b(SARS-CoV-2)\u5f15\u8d77\u7684COVID-19\u5927\u6d41\u884c\uff0c\u8feb\u5207\u9700\u8981\u6709\u6548\u7684\u9884\u9632\u548c\u6cbb\u7597\u836f\u7269\u3002RNA\u4f9d\u8d56\u6027RNA\u805a\u5408\u9176(RdRp)\u5bf9\u75c5\u6bd2RNA\u57fa\u56e0\u7ec4\u7684\u590d\u5236\u548c\u8f6c\u5f55\u81f3\u5173\u91cd\u8981\uff0c\u5728\u51a0\u72b6\u75c5\u6bd2\u4e2d\u9ad8\u5ea6\u4fdd\u5b88;\u56e0\u6b64\uff0c\u5b83\u662f\u6291\u5236\u51a0\u72b6\u75c5\u6bd2\u611f\u67d3\u7684\u6f5c\u5728\u9776\u70b9\u3002<\/p>\n
\u5728\u672c\u7814\u7a76\u4e2d\uff0c\u6211\u4eec\u901a\u8fc7\u4fee\u6539\u5148\u524d\u62a5\u9053\u7684\u57fa\u4e8e\u7ec6\u80de\u7684MERS-CoV -2 RdRp\u6d3b\u6027\u6d4b\u5b9a\u7cfb\u7edf\uff0c\u751f\u6210\u4e86\u57fa\u4e8e\u7ec6\u80de\u7684SARS-CoV-2 RdRp\u6d3b\u6027\u6d4b\u5b9a\u7cfb\u7edf\uff0c\u4ee5\u7b5b\u9009SARS-CoV-2 RdRp\u6291\u5236\u5242\u3002\u8be5\u68c0\u6d4b\u7cfb\u7edf\u7531\u7f16\u7801SARS-CoV-2 RdRp\u7684\u8868\u8fbe\u8d28\u7c92\u548cRdRp\u6d3b\u6027\u62a5\u544a\u8d28\u7c92\u7ec4\u6210\u3002\u8f6c\u67d3\u540e\u8367\u5149\u6cd5\u53ef\u65b9\u4fbf\u5730\u68c0\u6d4b\u7ec6\u80de\u5185RdRp\u6d3b\u6027\u3002<\/p>\n
\u6211\u4eec\u901a\u8fc7\u514d\u75ab\u8367\u5149\u67d3\u8272\u8bc1\u5b9e\u4e86SARS-CoV-2 RdRp\u590d\u5236\u53cc\u94feRNA\uff0c\u5e76\u5229\u7528\u8be5\u7cfb\u7edf\u8bc1\u5b9e\u4e86\u745e\u5fb7\u897f\u97e6\uff08Remdesivir\uff09\u548c\u77f3\u849c\u78b1\uff08Lycorine\uff09\u5bf9RdRp\u6d3b\u6027\u7684\u6291\u5236\u3002\u8ba1\u7b97\u51fa\u8be5\u7cfb\u7edf\u7684z\u56e0\u5b50\u4e3a0.798\uff0c\u8868\u660e\u8be5\u9ad8\u901a\u91cf\u7b5b\u9009\u7cfb\u7edf\u5177\u6709\u826f\u597d\u7684\u91cd\u73b0\u6027\u548c\u53ef\u9760\u6027\u3002<\/p>\n
\u6700\u540e\uff0c\u6211\u4eec\u5bf9\u6838\u82f7\u548c\u6838\u82f7\u9178\u7c7b\u4f3c\u7269\u8fdb\u884c\u7b5b\u9009\uff0c\u786e\u5b9a\u963f\u5fb7\u798f\u97e6\u916f\u3001\u6069\u66ff\u4ed6\u6ee8\u3001\u66ff\u6bd4\u592b\u5b9a\u3001\u6069\u66ff\u5361\u97e6\u6c34\u5408\u7269\u3001\u5417\u5549\u80cd\u548c\u5229\u798f\u5e73\u4e3a\u65b0\u578bSARS-CoV-2 RdRp\u6291\u5236\u5242\u548cCOVID-19\u6cbb\u7597\u5019\u9009\u836f\u7269\u3002\uff08\u90e8\u5206\u5185\u5bb9\u8282\u7565\uff09<\/p>\n
\u6574\u4e2a\u7814\u7a76\u6700\u6838\u5fc3\u7684\u5c31\u662f\u4e0b\u8868\uff1a<\/p>\n
\u8fd9\u7bc7\u6587\u7ae0\u62a5\u9053\u76d0\u9178\u5417\u5549\u80cd\u53ef\u5728100\u03bcM\u6d53\u5ea6\u65f6\u5019\u6291\u5236\u75c5\u6bd2RdRp\u9176\u6d3b\u602776%\uff0c\u4e0e6.7\u03bcM\u6d53\u5ea6\u7684\u745e\u5fb7\u897f\u97e6\u76f8\u5f53\u3002<\/p>\n
\u4f5c\u8005\u7684\u8bc4\u4ef7\u662f\uff1aIn addition, we found that moroxydine, a broad antiviral agent against DNA and RNA viruses [28] and rifampin, a macrocyclic antibiotic for tuberculosis [38], repressed SARS-CoV-2 RdRp activity moderately.<\/p>\n
\u4e5f\u5c31\u662f\u8bf4\uff1a\u4f5c\u8005\u8ba4\u4e3a\u76d0\u9178\u5417\u5549\u80cd\u6709\u8f7b\u5ea6\u6291\u5236\u65b0\u51a0\u75c5\u6bd2RdRp\u7684\u4f5c\u7528\u3002\u5b9e\u9a8c\u6570\u636e\u770b\u76d0\u9178\u5417\u5549\u80cd\u4e0e\u745e\u5fb7\u897f\u97e6\u6bd4\u8d77\u6765\u8fd8\u662f\u5dee\u8fdc\u4e86\u3002<\/p>\n
\u5230\u5e95\u600e\u4e48\u56de\u4e8b\u5462\uff1f<\/p>\n
\u63a5\u4e0b\u6765\u770b\u7b2c\u4e8c\u7bc7\u7814\u7a76\u62a5\u9053\u7684\u65f6\u5019\uff0c\u5c31\u611f\u89c9\u80fd\u591f\u89e3\u91ca\u5f97\u901a\u4e86\u3002<\/p>\n
\u8fd9\u4e2a\u5b9e\u9a8c\u4e2d\u7528\u4f5c\u6807\u7684\u745e\u5fb7\u897f\u97e6\u5927\u5bb6\u90fd\u5df2\u7ecf\u5f88\u719f\u6089\u4e86\uff0c\u987a\u9053\u79d1\u666e\u4e00\u4e0b\uff1a\u77f3\u849c\u53e6\u5916\u4e00\u4e2a\u54cd\u5f53\u5f53\u7684\u540d\u5b57\u53eb\u5f7c\u5cb8\u82b1\uff0c\u770b\u6765\u65b0\u51a0\u75c5\u6bd2\u4e5f\u9003\u4e0d\u4e86\u53bb\u5f7c\u5cb8\u3002\u6240\u4ee5\u6587\u7ae0\u63a8\u5d07\u7684\u77f3\u849c\u662f\u5148\u522b\u8003\u8651\u4e86\u3002<\/p>\n
\u767e\u5ea6\u8fd8\u641c\u5230\u6709\u4e89\u8bae\uff0c\u8fd9\u4e8b\u5927\u5bb6\u614e\u91cd\u5bf9\u5f85\u6bd4\u8f83\u597d\uff0c\u4e00\u5207\u90fd\u4e0e\u5242\u91cf\u6709\u5173\u3002<\/p>\n
\u7b2c\u4e8c\u7bc7:<\/p>\n
2. ‘Repurposing of FDA-approved antivirals, antibiotics, anthelmintics, antioxidants, and cell protectives against SARS-CoV-2 papain-like protease’<\/p>\n
J Biomol Struct Dyn. 2021 Sep;39(14):5129-5136.<\/p>\n
doi: 10.1080\/07391102.2020.1784291. Epub 2020 Jun 29.<\/p>\n
\u5148\u770b\u6458\u8981\uff1a<\/p>\n
SARS-CoV-2\u6216\u51a0\u72b6\u75c5\u6bd2\u75c519 (COVID-19)\u662f\u4e00\u79cd\u8fc5\u901f\u4f20\u64ad\uff0c\u9ad8\u5ea6\u4f20\u67d3\u6027\uff0c\u6709\u65f6\u751a\u81f3\u81f4\u547d\u7684\u75be\u75c5\uff0c\u836f\u7269\u7814\u53d1\u548c\u75ab\u82d7\u5f00\u53d1\u81f3\u5173\u91cd\u8981\u3002SARS-CoV-2\u6728\u74dc\u86cb\u767d\u9176\u7528\u4e8e\u7b5b\u90091697\u79cd\u7ecfFDA\u6279\u51c6\u7684\u4e34\u5e8a\u836f\u7269\u3002<\/p>\n
SARS-CoV-2 \u6728\u74dc\u86cb\u767d\u9176\u7ed3\u5408\u6548\u679c\u6700\u597d\u7684\u836f\u7269\u5305\u62ec\u4e09\u79cd\u7ec6\u80de\u4fdd\u62a4\u548c\u6297\u6c27\u5316\u5242(NAD+\u3001\u69f2\u76ae\u82f7\u548c\u6c27\u9170\u5316\u916e)\u3001\u4e09\u79cd\u6297\u75c5\u6bd2\u836f\u7269(\u5229\u6258\u90a3\u97e6\u3001\u5417\u5549\u80cd\u548c\u624e\u90a3\u7c73\u97e6)\u3001\u4e24\u79cd\u6297\u83cc\u5242(\u591a\u5229\u57f9\u5357\u548c\u78fa\u80fa\u5627\u5576)\u3001\u4e24\u79cd\u6297\u764c\u836f\u7269\u3001\u4e09\u79cd\u82ef\u5e76\u54aa\u5511\u7c7b\u6297\u866b\u836f\u3001\u4e00\u79cd\u6297\u9178\u836f(\u6cd5\u83ab\u66ff\u4e01)\u3001\u4e09\u79cd\u6297\u9ad8\u8840\u538bACE\u53d7\u4f53\u963b\u6ede\u5242(\u574e\u5730\u6c99\u5766\u3001\u6c2f\u6c99\u5766\u548c\u7f2c\u6c99\u5766)\u548c\u5176\u4ed6\u5404\u79cd\u5168\u8eab\u6216\u5c40\u90e8\u4f5c\u7528\u836f\u7269\u3002<\/p>\n
\u8fd9\u4e9b\u836f\u7269\u7684\u7ed3\u5408\u6a21\u5f0f\u4f18\u4e8e\u5148\u524d\u9274\u5b9a\u7684SARS CoV\u6728\u74dc\u86cb\u767d\u9176\u6291\u5236\u52426-\u5def\u57fa\u560c\u5464(6-MP)\uff0c\u8fd9\u8868\u660e\u8fd9\u4e9b\u836f\u7269\u6709\u53ef\u80fd\u88ab\u91cd\u65b0\u5229\u7528\u6765\u6cbb\u7597COVID-19\u3002\u672c\u6587\u63d0\u4f9b\u7684\u836f\u7269\u6e05\u5355\u662fCOVID-19\u60a3\u8005\u4e34\u5e8a\u5e94\u7528\u7684\u6307\u5bfc\uff0c\u4e5f\u662f\u8fdb\u4e00\u6b65\u6297\u75c5\u6bd2\u7814\u7a76\u7684\u6307\u5bfc\u3002\uff08\u90e8\u5206\u5185\u5bb9\u8282\u7565\uff09<\/p>\n
\u4e5f\u5c31\u662f\u8bf4\uff0c\u8be5\u7814\u7a76\u67e5\u7b5b\u9009\u4e861697\u79cd\u88ab\u7f8e\u56fdFDA\u6279\u51c6\u7528\u4e8e\u4e34\u5e8a\u7684\u836f\u7269\uff0c\u5176\u4e2d\u4e09\u79cd\u6297\u75c5\u6bd2\u836f\u7269\uff1a\u5229\u6258\u90a3\u97e6\u3001\u5417\u5549\u80cd\u548c\u624e\u90a3\u7c73\u97e6\u4e0e\u75c5\u6bd2\u86cb\u767d\u5177\u6709\u9ad8\u7ed3\u5408\u529b\u3002<\/p>\n
\u5229\u6258\u90a3\u97e6\u662f\u5927\u540d\u9f0e\u9f0e\u7684P\u836f\u7684\u7ec4\u6210\u6210\u5206\u4e4b\u4e00\uff0c\u80fd\u591f\u4e0e\u75c5\u6bd2\u7ed3\u5408\uff0c\u4f46\u662f\u5bf9RdRp\u6d3b\u6027\u7684\u6291\u5236\u7387\u4f3c\u4e4e\u5e76\u4e0d\u90a3\u4e48\u7406\u60f3\u3002<\/p>\n
\u7136\u800c\uff0c\u8fd9\u4e24\u7bc7\u7814\u7a76\u62a5\u9053\u653e\u4e00\u8d77\uff0c\u5417\u5549\u80cd\u6cbb\u7597\u65b0\u51a0\u75c5\u6bd2\u611f\u67d3\u4e5f\u8bb8\u8fd8\u771f\u6709\u53ef\u4ee5\u8bf4\u9053\u7684\u3002\u4e3a\u4ec0\u4e48\u5462\uff1f<\/p>\n
\u867d\u7136\u5417\u5549\u80cd\u5728100\u03bcM\u53ef\u4ee5\u6709\u6548\u6291\u5236\u65b0\u51a0\u75c5\u6bd2\uff0c\u4f46\u662f\u5417\u5549\u80cd\u4e0e\u53d7\u75c5\u6bd2\u611f\u67d3\u7ec6\u80de\u7684\u7ed3\u5408\u529b\u9ad8\uff0c\u90a3\u4e48\u5f88\u5bb9\u6613\u5728\u7ec6\u80de\u4e2d\u8fbe\u5230\u6709\u6548\u6d53\u5ea6\u3002<\/p>\n
\u745e\u5fb7\u897f\u97e6\u867d\u7136\u53ef\u4ee5\u8f83\u4f4e\u6d53\u5ea6\u6709\u6548\u6291\u5236RNA\u805a\u5408\u9176\uff0c\u4f46\u662f\u9700\u8981\u76f8\u5f53\u7ec4\u7ec7\u6db2\u6d53\u5ea6\u624d\u80fd\u8fbe\u5230\u8fdb\u5165\u7ec6\u80de\u6709\u6548\u6d53\u5ea6\u836f\u7269\u91cf\uff0c\u8fd9\u6837\u5c31\u9700\u8981\u4eba\u4f53\u9700\u8981\u6444\u5165\u7684\u603b\u836f\u7269\u91cf\u6bd4\u8f83\u9ad8\u3002<\/p>\n
\u53e6\u5916\uff0c\u745e\u5fb7\u897f\u97e6\u53e3\u670d\u751f\u7269\u5229\u7528\u5ea6\u6781\u4f4e\uff0c\u9700\u8981\u9759\u8109\u7ed9\u836f\u3002\u800c\u5417\u5549\u80cd\u5219\u53ef\u4ee5\u53e3\u670d\u7ed9\u836f\u3002\u5b89\u5168\u6027\u65b9\u9762\uff0c\u5417\u5549\u80cd\u7684\u4eba\u4f53\u5b89\u5168\u6027\u65e9\u5c31\u5f97\u5230\u9a8c\u8bc1\uff0c\u6709\u6548\u6d53\u5ea6\u548c\u6bd2\u6027\u6d53\u5ea6\u7684\u68af\u5ea6\u8de8\u5ea6\u6bd4\u8f83\u9ad8\uff0c\u4f46\u662f\u65e0\u8bba\u745e\u5fb7\u897f\u97e6\u8fd8\u662f\u5229\u6258\u90a3\u97e6\uff0c\u6709\u6548\u6d53\u5ea6\u548c\u6bd2\u6027\u6d53\u5ea6\u7684\u68af\u5ea6\u8de8\u5ea6\u5c31\u6ca1\u90a3\u4e48\u5927\u4e86\u3002<\/p>\n
\u66f4\u91cd\u8981\u7684\u662f\u5417\u5549\u80cd\u513f\u7ae5\u53ef\u4ee5\u7528\uff0c\u7528\u6cd5\uff1a\u53e3\u670d\uff0c\u6210\u4eba\uff1a\u4e00\u6b210.2g\uff0c\u4e00\u65e53\uff5e4\u6b21\u3002\u5c0f\u513f\uff1a\u6309\u4f53\u91cd\u4e00\u65e510mg\/kg\uff0c\u52063\u6b21\u670d\u7528\u3002\u76ee\u524d\u6765\u8bf4\uff0c\u5c1a\u6ca1\u6709\u53ef\u4ee5\u5728\u5c0f\u513f\u4f7f\u7528\u7684\u6291\u5236\u65b0\u51a0\u75c5\u6bd2\u836f\u7269\uff0c\u5982\u679c\u75c5\u6bd2\u7075\u53ef\u4ee5\u6291\u5236\u65b0\u51a0\u75c5\u6bd2\u611f\u67d3\uff0c\u90a3\u4e48\u90a3\u4e9b\u5c0f\u513f\u4e2d-\u91cd\u75c7\u65b0\u51a0\u75c5\u6bd2\u611f\u67d3\u60a3\u513f\u5c31\u6709\u6cbb\u7597\u7684\u5e0c\u671b\u3002<\/p>\n
\u81f3\u4e8e\u56e0\u4e3a\u65b0\u51a0\u9633\u6027\u53bb\u533b\u9662\u8981\u6c42\u914d\u5417\u5549\u80cd\uff1f\u5927\u6982\u7387\u662f\u914d\u4e0d\u5230\u7684\uff0c\u4e2d\u56fd\u7684\u5386\u6b21\u6307\u5357\u90fd\u6ca1\u6709\u628a\u5417\u5549\u80cd\u4f5c\u4e3a\u65b0\u51a0\u75c5\u6bd2\u611f\u67d3\u6cbb\u7597\u836f\u7269\u7684\u3002\u600e\u4e48\u914d\u53ea\u6709\u81ea\u5df1\u52a8\u8111\u7b4b\u4e86\uff0c\u7f51\u53cb\u63d0\u4f9b\u7684\u65b9\u6cd5\u5012\u662f\u53ef\u4ee5\u8003\u8651\uff0c\u4f46\u662f\u7528\u836f\u8fd8\u9700\u8981\u5728\u533b\u751f\u6307\u5bfc\u4e0b\u4f7f\u7528\uff0c\u6bd5\u7adf\u7528\u836f\u5c31\u6709\u7981\u5fcc\u4e8b\u5b9c\uff0c\u518d\u5b89\u5168\uff0c\u518d\u513f\u7ae5\u53ef\u4ee5\u7528\u7684\u836f\u7269\uff0c\u8fd8\u662f\u9700\u8981\u614e\u91cd\u3002\u90a3\u79cd\u88ab\u65b0\u534e\u793e\u6279\u7684\u5e7c\u513f\u56ed\u4eba\u624b\u4e00\u74f6\u75c5\u6bd2\u7075\u6295\u5582\u7684\u505a\u6cd5\u662f\u4e0d\u53ef\u53d6\u7684\u3002<\/p>\n
\u53e6\u4e00\u65b9\u9762\uff0c\u611f\u67d3\u65b0\u51a0\u75c5\u6bd2\uff0c\u4ec0\u4e48\u60c5\u51b5\u4e0b\u9700\u8981\u7528\u6297\u75c5\u6bd2\u6cbb\u7597\uff0c\u4e5f\u662f\u8981\u533a\u522b\u5bf9\u5f85\u7684\u3002\u5728\u6709\u9ad8\u5371\u56e0\u7d20\u7684\u60c5\u51b5\u4e0b\uff0c\u600e\u4e48\u9009\uff1f<\/p>\n","protected":false},"excerpt":{"rendered":"
\u6628\u5929\u94c1\u7c89\u7fa4\u91cc\u9762\u804a\u4e86\u94c1\u7c89\u533b\u751f\u63a8\u8350\u7684\u65b0\u51a0\u75c5\u6bd2\u6cbb\u7597\u836f\u7269\uff1a\u75c5\u6bd2\u7075\u3002 \u7b2c\u4e00\u6b21\u542c\u8bf4\u8fd9\u4e2a\u836f\u7269\u80fd … \u7ee7\u7eed\u9605\u8bfb